The C-terminal olfactomedin (OLF) domain of myocilin houses ∼90% of disease-causing mutations (Fig. 1), making the heritable subtype of glaucoma attractive for precision medicine and disease-modifying therapeutics (12, 15). Here, MYOC is linked to glaucoma.